Translational Oncology

Translational Oncology is an open-access oncology journal published by Elsevier that bridges laboratory cancer research and clinical practice, launched in 2008 and holding a 2025 Journal Impact Factor of 4.9.《转化肿瘤学》（Translational Oncology）由（Elsevier）以开放获取方式出版，2008 年创刊，致力于贯通肿瘤实验室研究与临床实践，2025 年期刊影响因子为 4.9。

Scope

• The journal's scope runs from risk assessment and cellular and molecular characterisation of human cancers to their prevention, detection, diagnosis and treatment.刊物范围涵盖人类癌症的风险评估、细胞与分子特征描述，以及预防、检测、诊断与治疗。
• Laboratory studies of novel therapeutic interventions are central, particularly where they carry a plausible route to clinical testing.新型治疗干预的实验室研究居于核心位置，尤其重视具备可行临床转化路径的工作。
• Clinical trials evaluating new treatment paradigms are published alongside that laboratory work.评估新治疗模式的临床试验与上述实验室研究并列刊载。
• The stated goal is to improve the clinical care of patients with cancer rather than to report bench findings in isolation.其明确目标是改善肿瘤患者的临床诊疗，而非孤立地报告实验室发现。
• Peer-reviewed manuscript types are Original Reports, Reviews and Editorials.同行评审稿件类型包括原创报告、综述与社论。
• Case reports fall outside the journal's remit and are not accepted.病例报告不属于刊物范围，不予接收。
• The journal belongs to Elsevier's Oncology Journal Network.刊物隶属（Elsevier）肿瘤学期刊网络。

History

• It was launched in 2008 by Neoplasia Press, the publisher behind the sister journal Neoplasia, with volume 1 opening that year.2008 年由（Neoplasia Press）创办，该机构同时出版姊妹刊《肿瘤形成》（Neoplasia），本刊第 1 卷同年问世。
• Early volumes carried four issues a year in 2008 and 2009, rising to six issues a year from 2010.2008 与 2009 年每年出版 4 期，2010 年起增至每年 6 期。
• The journal moved to twelve issues a year in 2019 and, from 2022, has numbered one volume per month.2019 年起改为每年 12 期，2022 年起大体每月一卷。
• Elsevier acquired Neoplasia Press in January 2015 and took over publication under the Neoplasia Press imprint.（Elsevier）于 2015 年 1 月收购（Neoplasia Press）并接手出版，初期沿用（Neoplasia Press）品牌。
• Its 2025 Journal Impact Factor is 4.9, after 4.1 in 2024, 4.803 in 2022 and 4.243 in 2021.2025 年期刊影响因子为 4.9，此前 2024 年为 4.1，2022 年为 4.803，2021 年为 4.243。
• It is indexed in SCIE, Scopus, PubMed/MEDLINE, PubMed Central and DOAJ, and is archived in CLOCKSS and Portico.刊物被（SCIE、Scopus、PubMed/MEDLINE、PubMed Central、DOAJ）收录，并由（CLOCKSS）与（Portico）长期存档。

Editors

• The journal is led by ten co-editors-in-chief rather than a single editor.刊物不设单一主编，而由 10 位共同主编领导。
• The first five are Mohammad Asim of the University of Surrey, Bushra Ateeq of IIT Kanpur, Yesim Gokmen-Polar of Emory University, Oliver Kramer of Mainz and Caroline E. Nunes-Xavier of Oslo University Hospital.共同主编包括萨里大学的（Mohammad Asim）、印度理工学院坎普尔分校的（Bushra Ateeq）、埃默里大学的（Yesim Gokmen-Polar）、美因茨大学医学中心的（Oliver Kramer）以及奥斯陆大学医院的（Caroline E. Nunes-Xavier）。
• The other five are Yu Sun of the Shanghai Institute of Nutrition and Health, Verna D.N.K. Vanderpuye of Accra's national radiotherapy centre, Monica Venere of Ohio State, Matthias Wirth of Gottingen and Jun Yan of Louisville.其余五位为中国科学院上海营养与健康研究所的（Yu Sun）、阿克拉国家放疗肿瘤与核医学中心的（Verna D.N.K. Vanderpuye）、俄亥俄州立大学的（Monica Venere）、哥廷根大学医学中心的（Matthias Wirth）与路易斯维尔大学的（Jun Yan）。
• Three further editors and a large international advisory review board support manuscript handling.另有 3 位编辑与规模庞大的国际顾问审稿委员会协助处理稿件。
• Manuscripts are handled through single anonymized review, normally with at least two independent referees, and the editors make the final decision.稿件采用单盲评审，通常至少送两位独立审稿人，最终决定由编辑作出。
• Pre-submission enquiries are required only for Spotlights and Perspectives, while Commentaries are commissioned.仅聚焦与展望两类稿件须事先向编辑部咨询，评论栏目则为约稿。
• Elsevier reports a median of 22 days from submission to first decision, 92 days to a decision after review and 7 days from acceptance to online publication.（Elsevier）公布的中位周期为：投稿至首次决定 22 天，送审后至决定 92 天，录用至在线发表 7 天。